Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

While caplacizumab is far from being a blockbuster candidate, the approval would validate Ablynx’s proprietary next-generation antibody ‘nanobody’ platform, which could deliver breakthroughs ...